MA43619B1 - Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci - Google Patents
Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ciInfo
- Publication number
- MA43619B1 MA43619B1 MA43619A MA43619A MA43619B1 MA 43619 B1 MA43619 B1 MA 43619B1 MA 43619 A MA43619 A MA 43619A MA 43619 A MA43619 A MA 43619A MA 43619 B1 MA43619 B1 MA 43619B1
- Authority
- MA
- Morocco
- Prior art keywords
- isoquinolin
- carboxamides
- preparation
- isoquinoline
- disorders
- Prior art date
Links
- KKSZSACCVDIWIE-UHFFFAOYSA-N isoquinoline-3-carboxamide Chemical class C1=CC=C2C=NC(C(=O)N)=CC2=C1 KKSZSACCVDIWIE-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015100 cartilage disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 abstract 1
- -1 isoquinoline compound Chemical class 0.000 abstract 1
- 150000002537 isoquinolines Chemical class 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662328255P | 2016-04-27 | 2016-04-27 | |
| PCT/US2017/029805 WO2017189829A1 (en) | 2016-04-27 | 2017-04-27 | Isoquinolin-3-yl carboxamides and preparation and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA43619A1 MA43619A1 (fr) | 2019-10-31 |
| MA43619B1 true MA43619B1 (fr) | 2020-10-28 |
Family
ID=60157337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43619A MA43619B1 (fr) | 2016-04-27 | 2017-04-27 | Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci |
Country Status (30)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| EP3370721A4 (en) | 2015-11-06 | 2019-05-22 | Samumed, LLC | TREATMENT OF OSTEOARTHRITIS |
| MX391850B (es) | 2015-12-10 | 2025-03-19 | Ptc Therapeutics Inc | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington |
| TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑 |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| CN115028617A (zh) * | 2016-05-24 | 2022-09-09 | 基因泰克公司 | Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途 |
| EP3464285B1 (en) | 2016-06-01 | 2022-09-21 | BioSplice Therapeutics, Inc. | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide |
| CN110709392B (zh) | 2017-03-30 | 2023-09-29 | 豪夫迈·罗氏有限公司 | 作为hpk1抑制剂的异喹啉 |
| SG11201911615WA (en) | 2017-06-05 | 2020-01-30 | Ptc Therapeutics Inc | Compounds for treating huntington's disease |
| MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| WO2019005980A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| WO2019079626A1 (en) * | 2017-10-19 | 2019-04-25 | Samumed, Llc | 6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE |
| US10653688B2 (en) | 2017-10-27 | 2020-05-19 | Samumed, Llc | 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof |
| WO2019084496A1 (en) | 2017-10-27 | 2019-05-02 | Samumed, Llc | 6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL- (HETEROARYL 5-CHAIN) CARBOXAMIDES, PREPARATION AND USE |
| US10703748B2 (en) * | 2017-10-31 | 2020-07-07 | Samumed, Llc | Diazanaphthalen-3-yl carboxamides and preparation and use thereof |
| AU2019243048A1 (en) | 2018-03-27 | 2020-10-15 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| CN112292373A (zh) | 2018-06-18 | 2021-01-29 | 詹森药业有限公司 | 作为RORγt的调节剂的吡啶基吡唑类 |
| CA3103771A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl pyrazoles as modulators of roryt |
| CA3103770A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Phenyl and pyridinyl substituted imidazoles as modulators of roryt |
| CA3103929A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Phenyl substituted pyrazoles as modulators of roryt |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| MX2020014098A (es) | 2018-06-27 | 2021-05-27 | Ptc Therapeutics Inc | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington. |
| BR112020026534A2 (pt) | 2018-06-27 | 2021-03-23 | Ptc Therapeutics, Inc. | Compostos de heteroarila para o tratamento da doença de huntington |
| TW202019905A (zh) | 2018-07-24 | 2020-06-01 | 瑞士商赫孚孟拉羅股份公司 | 異喹啉化合物及其用途 |
| TW202024053A (zh) | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| EP3911317A2 (en) | 2019-01-17 | 2021-11-24 | BioSplice Therapeutics, Inc. | Methods of treating cartilage disorders through inhibition of clk and dyrk |
| WO2021007378A1 (en) * | 2019-07-11 | 2021-01-14 | Ptc Therapeutics, Inc. | Compounds for use in treating huntington's disease |
| WO2021004547A1 (en) * | 2019-07-11 | 2021-01-14 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of hpk1 |
| EP4055015B1 (en) * | 2019-11-08 | 2025-04-02 | Nerviano Medical Sciences S.r.l. | Gem-disubstituted heterocyclic compounds and their use as idh inhibitors |
| US20230193265A1 (en) * | 2020-05-20 | 2023-06-22 | Osaka University | Cug repeat sequence binding agent |
| CN117088876A (zh) * | 2020-10-28 | 2023-11-21 | 杭州阿诺生物医药科技有限公司 | 一种高活性Wnt通路抑制剂化合物 |
| EP4244213A4 (en) * | 2020-11-10 | 2024-11-20 | Foghorn Therapeutics Inc. | COMPOUNDS AND USES THEREOF |
| TW202321244A (zh) * | 2021-07-26 | 2023-06-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Ｗｎｔ通路抑制劑化合物 |
| TW202334157A (zh) * | 2022-01-29 | 2023-09-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Ｗｎｔ通路抑制劑化合物 |
| CN117396482A (zh) * | 2022-07-28 | 2024-01-12 | 杭州阿诺生物医药科技有限公司 | 一种Wnt通路抑制剂化合物 |
| WO2024022365A1 (zh) * | 2022-07-28 | 2024-02-01 | 杭州阿诺生物医药科技有限公司 | 一种Wnt通路抑制剂化合物 |
| WO2024238620A1 (en) * | 2023-05-17 | 2024-11-21 | Woolsey Pharmaceuticals, Inc. | Methods of treating traumatic encephalopathy syndrome |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
| US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| GB9414139D0 (en) | 1994-07-13 | 1994-08-31 | Smithkline Beecham Plc | Novel compounds |
| ES2131463B1 (es) | 1997-04-08 | 2000-03-01 | Lilly Sa | Derivados de ciclopropilglicina con propiedades farmaceuticas. |
| DE19746287A1 (de) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
| DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
| US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
| RU2331640C2 (ru) | 1999-05-21 | 2008-08-20 | Бристол-Маерс Сквибб Ко. | Пирролтриазиновые ингибиторы киназ |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| CA2407573C (en) | 2000-04-27 | 2011-09-13 | Yamanouchi Pharmaceutical Co. Ltd. | Imidazopyridine derivatives |
| EP1401831A1 (en) | 2001-07-03 | 2004-03-31 | Chiron Corporation | Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
| BR0213562A (pt) | 2001-10-26 | 2004-08-31 | Aventis Pharma Inc | Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna |
| WO2003035005A2 (en) | 2001-10-26 | 2003-05-01 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
| FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| WO2003070236A2 (en) | 2002-02-19 | 2003-08-28 | Pharmacia Italia S.P.A. | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents |
| CA2476665A1 (en) | 2002-02-19 | 2003-08-28 | Pharmacia Corporation | Tricyclic pyrazole derivatives for the treatment of inflammation |
| BR0311291A (pt) | 2002-05-17 | 2005-03-29 | Pharmacia Italia Spa | Derivados de aminoindazol ativos como inibidores da cinase, processo para sua preparação e composições farmacêuticas compreendendo os mesmos |
| KR20050004214A (ko) | 2002-05-31 | 2005-01-12 | 에자이 가부시키가이샤 | 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물 |
| DE60319820T2 (de) | 2002-06-04 | 2009-03-26 | Schering Corp. | Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien |
| GB0218625D0 (en) | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| FR2845382A1 (fr) | 2002-10-02 | 2004-04-09 | Sanofi Synthelabo | Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique |
| WO2004076450A1 (en) | 2003-02-27 | 2004-09-10 | J. Uriach Y Compañia S.A. | Pyrazolopyridine derivates |
| GB0310867D0 (en) | 2003-05-12 | 2003-06-18 | Novartis Ag | Organic compounds |
| PL1651612T3 (pl) | 2003-07-22 | 2012-09-28 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
| CN1829713A (zh) | 2003-07-30 | 2006-09-06 | 辉瑞大药厂 | 3,5二取代的吲唑化合物、药物组合物和介导或抑制细胞增殖的方法 |
| US7008953B2 (en) | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| WO2005014554A1 (en) | 2003-08-08 | 2005-02-17 | Astex Therapeutics Limited | 1h-indazole-3-carboxamide compounds as mapkap kinase modulators |
| EP1692113B1 (en) | 2003-11-14 | 2017-09-27 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
| EP1532980A1 (en) | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
| FR2867778B1 (fr) | 2004-03-16 | 2006-06-09 | Sanofi Synthelabo | Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme |
| JP4995075B2 (ja) | 2004-03-25 | 2012-08-08 | メモリー・ファーマシューティカルズ・コーポレイション | インダゾール、ベンゾチアゾール、ベンゾイソチアゾール、ベンズイソキサゾール、ならびにそれらの調製および使用 |
| JP2007534692A (ja) | 2004-04-22 | 2007-11-29 | メモリー・ファーマシューティカルズ・コーポレイション | インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用 |
| US20060074102A1 (en) | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
| EP2239262A3 (en) | 2004-07-27 | 2011-10-19 | SGX Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| WO2006024945A1 (en) | 2004-09-03 | 2006-03-09 | Pfizer Inc. | Pharmaceutical compositions comprising a cdk inhibitor |
| WO2006054143A1 (en) | 2004-11-17 | 2006-05-26 | Pfizer Inc. | Polymorphs of {5-[3-(4,6-difluoro-1h-benzoimidazol-2-yl)-1h-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine |
| US20060116519A1 (en) | 2004-11-17 | 2006-06-01 | Agouron Pharmaceuticals, Inc. | Synthesis of 5-bromo-4-methyl-pyridin-3-ylmethyl)-ethyl-carbamic acid tert-butyl ester |
| US20060127388A1 (en) | 2004-12-10 | 2006-06-15 | Wyeth | Variants of glycogen synthase kinase 3 and uses thereof |
| US20060142247A1 (en) | 2004-12-17 | 2006-06-29 | Guy Georges | Tricyclic heterocycles |
| WO2006079055A2 (en) | 2005-01-24 | 2006-07-27 | Neurosystec Corporation | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues |
| US7541367B2 (en) | 2005-05-31 | 2009-06-02 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| AR057987A1 (es) | 2005-11-24 | 2008-01-09 | Astrazeneca Ab | Compuestos agonistas de cb1 (receptor cannabinoide) |
| JP2009521408A (ja) | 2005-12-02 | 2009-06-04 | サートリス ファーマシューティカルズ， インコーポレイテッド | Ｃｄｃ２様キナーゼ（ＣＬＫ）のモジュレータおよびその使用方法 |
| BRPI0709082A2 (pt) | 2006-03-23 | 2011-06-28 | Hoffmann La Roche | derivados de indazol substituìdos, sua fabricação e uso como agentes farmacêuticos |
| MX2008012482A (es) | 2006-03-31 | 2008-10-10 | Abbott Lab | Compuestos de indazol. |
| CA2651072A1 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| WO2008061109A2 (en) | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| EP1932830A1 (en) | 2006-12-11 | 2008-06-18 | The Genetics Company, Inc. | Sulfonamides and their use as a medicament |
| DE602006021591D1 (de) | 2006-12-11 | 2011-06-09 | Genetics Co Inc | Aromatische 1,4-DI-Carboxylamide und deren Verwendung |
| EP2121608B1 (en) | 2006-12-14 | 2012-11-14 | Bayer Intellectual Property GmbH | Dihydropyridine derivatives useful as protein kinase inhibitors |
| CA2683398A1 (en) | 2007-04-10 | 2008-10-16 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| EP2148865B1 (en) | 2007-04-30 | 2017-05-17 | Genentech, Inc. | Pyrazole inhibitors of wnt signaling |
| CN101730531A (zh) | 2007-05-10 | 2010-06-09 | 阿瓦隆药品公司 | 芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途 |
| US8304408B2 (en) | 2007-05-24 | 2012-11-06 | The Regents Of The University Of California | Wnt signaling inhibitors, and methods for making and using them |
| CL2008001540A1 (es) | 2007-05-29 | 2009-05-22 | Sgx Pharmaceuticals Inc | Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer. |
| WO2008154241A1 (en) | 2007-06-08 | 2008-12-18 | Abbott Laboratories | 5-heteroaryl substituted indazoles as kinase inhibitors |
| EP2157859A4 (en) | 2007-06-19 | 2011-01-12 | Takeda Pharmaceutical | INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE |
| US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| US20100190736A1 (en) | 2007-08-02 | 2010-07-29 | Nerviano Medical Sciences S.R.L. | Morpholinyl anthracycline derivative combined with protein kinase inhibitors |
| WO2009023193A1 (en) | 2007-08-15 | 2009-02-19 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| WO2009061345A2 (en) | 2007-11-07 | 2009-05-14 | Cornell Research Foundation, Inc. | Targeting cdk4 and cdk6 in cancer therapy |
| WO2009085226A2 (en) | 2007-12-21 | 2009-07-09 | Sirtris Pharmaceuticals, Inc. | Inhibitors of cdc2-like kinases (clks) and methods of use thereof |
| KR101061599B1 (ko) | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| CN101440092B (zh) | 2008-12-25 | 2010-11-17 | 浙江大学 | 2-吲唑-4-氮杂吲哚-5-氨基衍生物及制备和应用 |
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| EP2408744A1 (en) | 2009-03-18 | 2012-01-25 | Schering Corporation | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase |
| CA2755768A1 (en) | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| JP2013500267A (ja) | 2009-07-23 | 2013-01-07 | ヴァンダービルト ユニバーシティー | ｍＧＬｕＲ４増強剤としての置換されたベンゾイミダゾールスルホンアミド類および置換されたインドールスルホンアミド類 |
| WO2011019648A1 (en) | 2009-08-10 | 2011-02-17 | Epitherix, Llc | Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof |
| CN102595900B (zh) | 2009-08-10 | 2015-07-15 | 萨穆梅德有限公司 | Wnt信号传导途径的吲唑抑制剂及其治疗用途 |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| US7998878B2 (en) | 2009-11-20 | 2011-08-16 | Eastman Kodak Company | Method for selective deposition and devices |
| PL3001903T3 (pl) | 2009-12-21 | 2018-03-30 | Samumed, Llc | 1H-pirazolo[3,4-b]pirydyny i ich zastosowania terapeutyczne |
| RS53500B1 (sr) | 2009-12-21 | 2015-02-27 | Array Biopharma, Inc. | Supstituisana jedinjenja n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-karboksamida kao cfms inhibitori |
| EP2552893B1 (en) | 2010-03-31 | 2014-10-29 | Actelion Pharmaceuticals Ltd. | Antibacterial isoquinolin-3-ylurea derivatives |
| EP2556058B1 (en) | 2010-04-06 | 2017-06-14 | Peter MacCallum Cancer Institute | Radioprotector compounds and methods |
| US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| PH12013501489A1 (en) | 2010-12-17 | 2013-08-28 | Hoffmann La Roche | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
| CN102558173B (zh) * | 2010-12-31 | 2015-05-20 | 广州源生医药科技有限公司 | 抑制wnt信号传导的化合物、组合物及其应用 |
| US8889684B2 (en) | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| MX2014001595A (es) | 2011-08-12 | 2014-04-14 | Hoffmann La Roche | Compuestos de imidazol, composiciones y metodos de uso. |
| SG10201914121YA (en) | 2011-09-14 | 2020-03-30 | Samumed Llc | Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors |
| WO2013169793A2 (en) | 2012-05-09 | 2013-11-14 | Ipierian, Inc. | Methods and compositions for tdp-43 proteinopathies |
| US9557993B2 (en) | 2012-10-23 | 2017-01-31 | Analog Devices Global | Processor architecture and method for simplifying programming single instruction, multiple data within a register |
| CN105120862A (zh) | 2013-01-08 | 2015-12-02 | 萨穆梅德有限公司 | Wnt信号途径的3-(苯并咪唑-2-基)-吲唑抑制剂及其治疗应用 |
| JP2016505041A (ja) | 2013-01-16 | 2016-02-18 | シグナル ファーマシューティカルズ，エルエルシー | 置換型ピロロピリミジン化合物、その組成物、およびこれらを用いた治療方法 |
| US9745271B2 (en) | 2014-03-20 | 2017-08-29 | Samumed, Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
| WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
| WO2016040188A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
| WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| CN114149432B (zh) | 2016-09-30 | 2024-07-05 | 斯坦福国际研究院 | 用于癌症治疗的双重clk/cdk1抑制剂 |
| WO2020006115A1 (en) | 2018-06-26 | 2020-01-02 | Betty Tam | Methods of treating cancer using a clk inhibitor |
| WO2020150545A1 (en) | 2019-01-17 | 2020-07-23 | Samumed, Llc | Pyrazole derivatives as modulators of the wnt/b-catenin signaling pathway |
-
2017
- 2017-04-26 AR ARP170101055A patent/AR108325A1/es active IP Right Grant
- 2017-04-27 SG SG10201914054SA patent/SG10201914054SA/en unknown
- 2017-04-27 MA MA43619A patent/MA43619B1/fr unknown
- 2017-04-27 DK DK17790416.6T patent/DK3448386T3/da active
- 2017-04-27 PL PL17790416T patent/PL3448386T3/pl unknown
- 2017-04-27 RS RS20210466A patent/RS61879B1/sr unknown
- 2017-04-27 AU AU2017258193A patent/AU2017258193B2/en active Active
- 2017-04-27 CA CA3022002A patent/CA3022002A1/en active Pending
- 2017-04-27 SM SM20210224T patent/SMT202100224T1/it unknown
- 2017-04-27 MY MYPI2018001772A patent/MY198966A/en unknown
- 2017-04-27 HU HUE17790416A patent/HUE054103T2/hu unknown
- 2017-04-27 SG SG11201809301YA patent/SG11201809301YA/en unknown
- 2017-04-27 EP EP17790416.6A patent/EP3448386B1/en active Active
- 2017-04-27 PE PE2018002194A patent/PE20190326A1/es unknown
- 2017-04-27 KR KR1020187034084A patent/KR102374844B1/ko active Active
- 2017-04-27 LT LTEP17790416.6T patent/LT3448386T/lt unknown
- 2017-04-27 MD MDE20190282T patent/MD3448386T2/ro unknown
- 2017-04-27 MX MX2018013174A patent/MX385859B/es unknown
- 2017-04-27 PT PT177904166T patent/PT3448386T/pt unknown
- 2017-04-27 SI SI201730725T patent/SI3448386T1/sl unknown
- 2017-04-27 WO PCT/US2017/029805 patent/WO2017189829A1/en not_active Ceased
- 2017-04-27 HR HRP20210607TT patent/HRP20210607T1/hr unknown
- 2017-04-27 CN CN201780037225.6A patent/CN109310690B/zh active Active
- 2017-04-27 EP EP25155985.2A patent/EP4559905A3/en active Pending
- 2017-04-27 JP JP2018556902A patent/JP6993985B2/ja active Active
- 2017-04-27 US US15/499,013 patent/US10106527B2/en active Active
- 2017-04-27 EP EP21159576.4A patent/EP3892276A1/en not_active Withdrawn
- 2017-04-27 ES ES17790416T patent/ES2865374T3/es active Active
- 2017-12-06 US US15/833,917 patent/US9951048B1/en active Active
-
2018
- 2018-01-30 US US15/884,112 patent/US10100038B2/en active Active
- 2018-09-13 US US16/130,842 patent/US10544128B2/en active Active
- 2018-10-18 IL IL262470A patent/IL262470B/en unknown
- 2018-10-23 PH PH12018502258A patent/PH12018502258A1/en unknown
- 2018-10-26 CL CL2018003065A patent/CL2018003065A1/es unknown
- 2018-11-14 CO CONC2018/0012299A patent/CO2018012299A2/es unknown
-
2019
- 2019-05-16 CL CL2019001343A patent/CL2019001343A1/es unknown
- 2019-12-04 US US16/703,321 patent/US10947217B2/en active Active
-
2021
- 2021-01-22 US US17/155,577 patent/US11548872B2/en active Active
- 2021-04-21 CY CY20211100344T patent/CY1124302T1/el unknown
-
2022
- 2022-11-18 US US17/990,133 patent/US12281097B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43619B1 (fr) | Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci | |
| MA43605B1 (fr) | Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci | |
| MA37450A1 (fr) | Inhibiteurs d'indazole du trajet de signal de wnt et leurs utilisations thérapeutiques | |
| MA64509B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA64121B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA46018A (fr) | Activateurs d'édition du génome | |
| TN2009000551A1 (fr) | Nouveaux composes chimiques | |
| MY184882A (en) | Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathyway inhibitors | |
| MA31156B1 (fr) | Modulateurs de partenaires de liaison de la sclerostine pour traiter des troubles lies aux os | |
| YU98003A (sh) | Supstituisana sulfonamidna jedinjenja, postupak za njihovu upotrebu kao leka za tretiranje poremećaja cns, gojaznosti i dijabetesa tipa ii | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| MA38284A1 (fr) | Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one | |
| MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
| MA49947B1 (fr) | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes | |
| MA32506B1 (fr) | Nouveaux composes | |
| ATE461697T1 (de) | Phospholipidderivate von valproinsäure und ihre kombinationen | |
| MA32158B1 (fr) | Thiazolyldihydroindazoles | |
| MA49839B1 (fr) | Inhibiteurs bicycliques de la histone déacétylase | |
| MA31902B1 (fr) | Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque | |
| FR3088542B1 (fr) | Composition cicatrisante comprenant une eau électrolysée | |
| MA44660B1 (fr) | (+) -azasetron pour son utilisation dans le traitement des troubles de l'oreille | |
| MA31385B1 (fr) | Utilisation d'inhibiteurs de hdac pour le traitement de la destruction osseuse | |
| MA44769B1 (fr) | Formulations destinées à une utilisation dans le traitement ou la prévention de maladies urologiques | |
| DE60326348D1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
| MA48970B1 (fr) | Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate |